ACADIA Pharmaceuticals Inc.
ACAD Healthcare Biotechnology
ACADIA Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 billion, up 11.9% from fiscal 2024. In the quarter to June 2026, revenue grew 16.4%, EPS grew 12.5% and free cash flow grew 50.3%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow ACAD
ACADIA Pharmaceuticals Inc. (ACAD) P/E ratio
As of 16 October 2026, ACADIA Pharmaceuticals Inc. (ACAD) trades at a P/E ratio of 8.5×. Over the past ten years it has ranged from 0.0× (June 2024) to 106× (July 2024); the current reading is higher than 81% of that period. That is in line with the Biotechnology industry median of 8.5× and below the Healthcare sector median of 23.0×.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 11.5× | (14.67%) |
| FY2024 | 13.5× | — |
| FY2023 | 0.0× | — |
| FY2022 | 0.0× | — |
| FY2021 | 0.0× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
| FY2016 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 11.2× | 12.65% |
| Mar 2026 | 10.0× | (13.30%) |
| Dec 2025 | 11.5× | (15.84%) |
| Sep 2025 | 13.7× | (15.65%) |
| 42 more quarters | Free account |
Against its own ten years
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| VKTX Viking Therapeutics, Inc. compare | n/m |
| TNGX Tango Therapeutics, Inc. compare | n/m |
| TARS Tarsus Pharmaceuticals, Inc. compare | n/m |
| RLAY Relay Therapeutics, Inc. compare | n/m |
| XENE Xenon Pharmaceuticals Inc. compare | n/m |
| IDYA IDEAYA Biosciences, Inc. compare | n/m |
| ACAD ACADIA Pharmaceuticals Inc. | 8.5× |
| ARQT Arcutis Biotherapeutics, Inc. compare | 131× |
| TLX Telix Pharmaceuticals Limited compare | — |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)